NZ598618A - Pharmaceutical combination for treating tumor - Google Patents
Pharmaceutical combination for treating tumorInfo
- Publication number
- NZ598618A NZ598618A NZ598618A NZ59861810A NZ598618A NZ 598618 A NZ598618 A NZ 598618A NZ 598618 A NZ598618 A NZ 598618A NZ 59861810 A NZ59861810 A NZ 59861810A NZ 598618 A NZ598618 A NZ 598618A
- Authority
- NZ
- New Zealand
- Prior art keywords
- antisense
- antibody
- fatty acid
- effective amount
- formula
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Oncology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US24301909P | 2009-09-16 | 2009-09-16 | |
| PCT/JP2010/066619 WO2011034210A1 (en) | 2009-09-16 | 2010-09-16 | Pharmaceutical combination for treating tumor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ598618A true NZ598618A (en) | 2014-10-31 |
Family
ID=43730802
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ598618A NZ598618A (en) | 2009-09-16 | 2010-09-16 | Pharmaceutical combination for treating tumor |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US9084815B2 (https=) |
| EP (1) | EP2477632A4 (https=) |
| JP (2) | JP5891168B2 (https=) |
| KR (1) | KR101760963B1 (https=) |
| CN (2) | CN102481302A (https=) |
| AR (1) | AR078182A1 (https=) |
| AU (1) | AU2010296307B2 (https=) |
| BR (1) | BR112012005896A2 (https=) |
| CA (1) | CA2772314A1 (https=) |
| IL (1) | IL218392A (https=) |
| MX (1) | MX2012003188A (https=) |
| NZ (1) | NZ598618A (https=) |
| RU (2) | RU2016103415A (https=) |
| SG (2) | SG179153A1 (https=) |
| TW (1) | TWI535436B (https=) |
| WO (1) | WO2011034210A1 (https=) |
| ZA (1) | ZA201201894B (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
| US20150099802A1 (en) * | 2013-10-03 | 2015-04-09 | Sucampo Ag | Selective tumor treatment |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
| CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
| US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
| TW224942B (https=) | 1990-04-04 | 1994-06-11 | Adka Ueno Kk | |
| US5302617A (en) | 1990-04-27 | 1994-04-12 | Kabushikikaisha Ueno Seiyaku Oyo Kenkyuio | Biochemical treatment with 15-dehydroxy-16-oxoprostaglandin compounds |
| DE69124415T2 (de) | 1990-04-27 | 1997-05-15 | Ueno Seiyaku Oyo Kenkyujo Kk | Verwendung von 15-Dehydroxy-16-Oxoprostaglandin bei der Behandlung von allergischen Erkrankungen |
| US5578643A (en) | 1992-05-20 | 1996-11-26 | Loyola University Of Chicago | Protective prostaglandins for use in conjunction with chemotherapeutic agents |
| US5438075A (en) * | 1993-03-30 | 1995-08-01 | Skubitz; Keith M. | Oral glutamine to reduce stomatitis |
| RU2071780C1 (ru) * | 1993-10-11 | 1997-01-20 | Научно-производственное предприятие "Фармэк" | Способ лечения медикаментозных эзофаго-гингиво-стоматитов |
| JPH0770054A (ja) | 1993-08-30 | 1995-03-14 | R Tec Ueno:Kk | 生化学的拮抗および疾患処置剤 |
| CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
| WO1997047595A1 (en) | 1996-06-10 | 1997-12-18 | R-Tech Ueno, Ltd. | Endothelin antagonist |
| TWI284535B (en) | 2000-03-24 | 2007-08-01 | Sucampo Ag | Apoptosis inhibitor |
| US6414016B1 (en) * | 2000-09-05 | 2002-07-02 | Sucampo, A.G. | Anti-constipation composition |
| TWI302100B (en) * | 2001-05-02 | 2008-10-21 | Sucampo Ag | Composition for treating drug-induced constipation |
| DE602004030245D1 (de) * | 2003-07-03 | 2011-01-05 | Sucampo Ag | Pharmazeutische magensaftresistent überzogene zusammensetzung enthaltend prostaglandin-analoga als chloridkanalöffner |
| US8202909B2 (en) | 2005-01-27 | 2012-06-19 | Sucampo Ag | Method for treating central nervous system disorders |
| CN101180096B (zh) * | 2005-03-21 | 2015-04-22 | 苏坎波公司 | 用于治疗粘膜疾病的方法和组合物 |
| US20060281818A1 (en) * | 2005-03-21 | 2006-12-14 | Sucampo Ag, North Carolina State University | Method for treating mucosal disorders |
| US20090012165A1 (en) | 2007-07-03 | 2009-01-08 | Sucampo Ag | Pharmaceutical combination of nsaid and prostaglandin compound |
-
2010
- 2010-09-15 US US12/882,794 patent/US9084815B2/en not_active Expired - Fee Related
- 2010-09-16 KR KR1020127009499A patent/KR101760963B1/ko not_active Expired - Fee Related
- 2010-09-16 AR ARP100103379A patent/AR078182A1/es unknown
- 2010-09-16 JP JP2012514010A patent/JP5891168B2/ja active Active
- 2010-09-16 BR BR112012005896A patent/BR112012005896A2/pt not_active IP Right Cessation
- 2010-09-16 RU RU2016103415A patent/RU2016103415A/ru not_active Application Discontinuation
- 2010-09-16 CN CN2010800410970A patent/CN102481302A/zh active Pending
- 2010-09-16 CN CN201611061998.1A patent/CN107050458A/zh active Pending
- 2010-09-16 WO PCT/JP2010/066619 patent/WO2011034210A1/en not_active Ceased
- 2010-09-16 SG SG2012018321A patent/SG179153A1/en unknown
- 2010-09-16 EP EP10817322.0A patent/EP2477632A4/en not_active Withdrawn
- 2010-09-16 RU RU2012114771/15A patent/RU2577700C2/ru not_active IP Right Cessation
- 2010-09-16 SG SG10201405467PA patent/SG10201405467PA/en unknown
- 2010-09-16 TW TW099131408A patent/TWI535436B/zh not_active IP Right Cessation
- 2010-09-16 MX MX2012003188A patent/MX2012003188A/es active IP Right Grant
- 2010-09-16 AU AU2010296307A patent/AU2010296307B2/en not_active Ceased
- 2010-09-16 NZ NZ598618A patent/NZ598618A/en not_active IP Right Cessation
- 2010-09-16 CA CA2772314A patent/CA2772314A1/en not_active Abandoned
-
2012
- 2012-02-29 IL IL218392A patent/IL218392A/en not_active IP Right Cessation
- 2012-03-14 ZA ZA2012/01894A patent/ZA201201894B/en unknown
-
2015
- 2015-06-15 US US14/739,242 patent/US20150272961A1/en not_active Abandoned
-
2016
- 2016-01-07 JP JP2016002010A patent/JP2016056191A/ja active Pending
- 2016-12-07 US US15/371,413 patent/US20170079986A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP2477632A4 (en) | 2013-06-12 |
| JP2013504520A (ja) | 2013-02-07 |
| SG10201405467PA (en) | 2014-10-30 |
| AR078182A1 (es) | 2011-10-19 |
| MX2012003188A (es) | 2012-04-30 |
| KR101760963B1 (ko) | 2017-07-24 |
| SG179153A1 (en) | 2012-04-27 |
| EP2477632A1 (en) | 2012-07-25 |
| CN102481302A (zh) | 2012-05-30 |
| ZA201201894B (en) | 2012-11-28 |
| KR20120081139A (ko) | 2012-07-18 |
| US9084815B2 (en) | 2015-07-21 |
| RU2577700C2 (ru) | 2016-03-20 |
| AU2010296307A1 (en) | 2012-04-05 |
| AU2010296307B2 (en) | 2016-02-11 |
| CN107050458A (zh) | 2017-08-18 |
| TWI535436B (zh) | 2016-06-01 |
| US20110064748A1 (en) | 2011-03-17 |
| JP2016056191A (ja) | 2016-04-21 |
| WO2011034210A1 (en) | 2011-03-24 |
| TW201116277A (en) | 2011-05-16 |
| JP5891168B2 (ja) | 2016-03-22 |
| RU2016103415A (ru) | 2018-11-22 |
| US20170079986A1 (en) | 2017-03-23 |
| CA2772314A1 (en) | 2011-03-24 |
| US20150272961A1 (en) | 2015-10-01 |
| RU2012114771A (ru) | 2013-10-27 |
| IL218392A0 (en) | 2012-04-30 |
| BR112012005896A2 (pt) | 2016-03-15 |
| IL218392A (en) | 2016-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220399T1 (hr) | Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost | |
| HRP20180104T1 (hr) | Materijal i postupci za liječenje ili prevenciju bolesti povezanih s her-3 | |
| Nguyen et al. | Enhancement of paclitaxel-mediated cytotoxicity in lung cancer cells by 17-allylamino geldanamycin: in vitro and in vivo analysis | |
| SG194048A1 (en) | Combinations of akt inhibitor compounds and chemotherapeutic agents, and methods of use | |
| AU2012229062A1 (en) | Overcoming resistance to ErbB pathway inhibitors | |
| SG10201906075VA (en) | Methods of treating cancer | |
| NZ610851A (en) | Compounds and compositions for the treatment of cancer | |
| RU2009132674A (ru) | Комбинированная терапия с использованием ингибиторов ангиогенеза | |
| JP2014034576A5 (https=) | ||
| RU2016122654A (ru) | Комбинированная терапия злокачественной опухоли с использованием ингибиторов бромодоменового и экстратерминального (вет) белка | |
| NZ630843A (en) | Treatment of brain cancer | |
| MX360404B (es) | Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr. | |
| DK2544674T3 (da) | Cdc7-kinaseinhibitorer og anvendelser deraf | |
| HRP20161114T1 (hr) | Sastavi inhibitora kinaze i njihova uporaba za liječenje raka i drugih bolesti povezanih s kinazama | |
| JP2018534289A5 (https=) | ||
| NZ707090A (en) | Synthetic lethality and the treatment of cancer | |
| NZ598618A (en) | Pharmaceutical combination for treating tumor | |
| EP2501385A1 (en) | Therapeutic combination comprising a cdc7 inhibitor and an antineoplastic agent | |
| Gatti et al. | Drug combinations with proteasome inhibitors in antitumor therapy | |
| Satolli et al. | Gastric cancer: The times they are a-changin’ | |
| RU2016147521A (ru) | Способы применения антител к ang2 | |
| JP2017514854A5 (https=) | ||
| MX2013014071A (es) | Combinacion de tratamiento de sinergia para el tratamiento del carcinoma de celula escamosa de cabeza y cuello. | |
| Gardner et al. | Current and future directions of clinical trials for ovarian cancer | |
| Li et al. | Comparison of gemcitabine combined with targeted agent therapy versus gemcitabine monotherapy in the management of advanced pancreatic cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 16 SEP 2017 BY HENRY HUGHES IP LIMITED Effective date: 20150430 |
|
| LAPS | Patent lapsed |